Header Logo

Connection

RAYNE ROUCE to Humans

Back to Details
This is a "connection" page, showing publications RAYNE ROUCE has written about Humans.
RAYNE ROUCE
Connection Strength
0.507
Humans
  1. How to democratize cell and gene therapy: A global approach. Mol Ther. 2025 May 07; 33(5):2082-2090.
    View in: PubMed
    Score: 0.025
  2. EBV and post-transplant lymphoproliferative disorder: a complex relationship. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):728-735.
    View in: PubMed
    Score: 0.024
  3. Cell and gene therapy accessibility. Science. 2024 08 02; 385(6708):475.
    View in: PubMed
    Score: 0.024
  4. Targeted cellular therapy for treatment of relapsed or refractory leukemia. Best Pract Res Clin Haematol. 2023 09; 36(3):101481.
    View in: PubMed
    Score: 0.022
  5. Access offsets poverty in quest for CAR T cells. Blood. 2023 02 09; 141(6):558-560.
    View in: PubMed
    Score: 0.021
  6. Reverse translational studies inform dual-targeted CAR T-cell design. Blood. 2022 08 04; 140(5):409-410.
    View in: PubMed
    Score: 0.021
  7. Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):487-493.
    View in: PubMed
    Score: 0.018
  8. Replacing CAR-T cell resistance with persistence by changing a single residue. J Clin Invest. 2020 06 01; 130(6):2806-2808.
    View in: PubMed
    Score: 0.018
  9. The earlier the better: timely mitigation of CRS. Blood. 2019 12 12; 134(24):2119-2120.
    View in: PubMed
    Score: 0.017
  10. Gene Therapy: Current Applications and Future Possibilities. Adv Pediatr. 2019 08; 66:37-54.
    View in: PubMed
    Score: 0.016
  11. Are we there yet? The never-ending quest for an Epstein-Barr virus vaccine. J Clin Invest. 2019 04 15; 129(5):1836-1838.
    View in: PubMed
    Score: 0.016
  12. Primed to Kill: CTV-1 Stimulated Haploidentical Natural Killer Cells for Consolidation of AML. Biol Blood Marrow Transplant. 2018 08; 24(8):1533-1535.
    View in: PubMed
    Score: 0.015
  13. Equal opportunity CAR T cells. Blood. 2017 06 22; 129(25):3275-3277.
    View in: PubMed
    Score: 0.014
  14. Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol. 2017 03; 176(5):688-704.
    View in: PubMed
    Score: 0.014
  15. Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov. 2016 06; 6(6):579-80.
    View in: PubMed
    Score: 0.013
  16. The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
    View in: PubMed
    Score: 0.013
  17. More than Memory: Potential of Adaptive Natural Killer Cells. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1534-6.
    View in: PubMed
    Score: 0.013
  18. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014 Nov; 21(6):476-81.
    View in: PubMed
    Score: 0.012
  19. Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025 Oct 28; 9(20):5249-5262.
    View in: PubMed
    Score: 0.006
  20. Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025 Oct 14; 9(19):5070-5084.
    View in: PubMed
    Score: 0.006
  21. Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Blood. 2025 Jun 19; 145(25):3041-3051.
    View in: PubMed
    Score: 0.006
  22. How I Approach Ethical Considerations for Pediatric Phase I CAR T-Cell Trials. Pediatr Blood Cancer. 2025 Aug; 72(8):e31802.
    View in: PubMed
    Score: 0.006
  23. Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
    View in: PubMed
    Score: 0.006
  24. New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis. Lancet Oncol. 2025 Apr; 26(4):e214-e224.
    View in: PubMed
    Score: 0.006
  25. Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Apr; 72(4):e31557.
    View in: PubMed
    Score: 0.006
  26. American Society of Hematology: building a comprehensive minority recruitment and retention professional program. Blood Adv. 2024 Dec 24; 8(24):6237-6247.
    View in: PubMed
    Score: 0.006
  27. Proceedings of the 2024 Third Annual ASTCT-NMDP ACCESS Initiative Workshop. Transplant Cell Ther. 2024 12; 30(12):1124-1138.
    View in: PubMed
    Score: 0.006
  28. Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024 07 09; 8(13):3544-3548.
    View in: PubMed
    Score: 0.006
  29. Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
    View in: PubMed
    Score: 0.006
  30. Enhancing pediatric access to cell and gene therapies. Nat Med. 2024 Jul; 30(7):1836-1846.
    View in: PubMed
    Score: 0.006
  31. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies. Transplant Cell Ther. 2024 08; 30(8):776-787.
    View in: PubMed
    Score: 0.006
  32. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.006
  33. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Transplant Cell Ther. 2024 06; 30(6):565-579.
    View in: PubMed
    Score: 0.006
  34. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
    View in: PubMed
    Score: 0.006
  35. Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023; 14:1239132.
    View in: PubMed
    Score: 0.006
  36. Bringing CAR T?cell therapy trials to underserved populations. Cancer Cell. 2023 12 11; 41(12):2007-2010.
    View in: PubMed
    Score: 0.006
  37. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):747-760.
    View in: PubMed
    Score: 0.005
  38. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2023 03; 29(3):165.e1-165.e7.
    View in: PubMed
    Score: 0.005
  39. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.005
  40. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 03 20; 40(9):945-955.
    View in: PubMed
    Score: 0.005
  41. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.005
  42. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.005
  43. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 11 10; 4(21):5414-5424.
    View in: PubMed
    Score: 0.005
  44. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
    View in: PubMed
    Score: 0.004
  45. Ponatinib use in two pediatric patients with relapsed Ph?+?ALL with ABL1 kinase domain mutations. Pediatr Hematol Oncol. 2019 11; 36(8):514-519.
    View in: PubMed
    Score: 0.004
  46. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. J Transl Med. 2019 07 24; 17(1):240.
    View in: PubMed
    Score: 0.004
  47. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
    View in: PubMed
    Score: 0.004
  48. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.004
  49. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.004
  50. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.004
  51. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 08 02; 25(8):1769-1781.
    View in: PubMed
    Score: 0.004
  52. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
    View in: PubMed
    Score: 0.004
  53. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
    View in: PubMed
    Score: 0.003
  54. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45.
    View in: PubMed
    Score: 0.003
  55. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
    View in: PubMed
    Score: 0.003
  56. A premature neonate with leukocytosis. Clin Pediatr (Phila). 2012 Jul; 51(7):692-3.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.